Literature DB >> 21048524

Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador.

Catherine Yen1, Julio A Armero Guardado, Patricia Alberto, David S Rodriguez Araujo, Carlos Mena, Elizabeth Cuellar, Jenny Brenda Nolasco, Lucia Helena De Oliveira, Desiree Pastor, Jacqueline E Tate, Umesh D Parashar, Manish M Patel.   

Abstract

BACKGROUND: A recent postlicensure study from El Salvador showed that the monovalent rotavirus vaccine conferred 76% protection against rotavirus hospitalizations. We further examined the impact of rotavirus vaccination on the national burden of childhood diarrhea to help assess the total public health benefits of vaccination.
METHODS: We compared all-cause diarrhea and rotavirus-specific hospitalization rates during prevaccine year 2006, with postvaccine years 2008 and 2009 in children < 5 years of age from 7 sentinel surveillance hospitals. We also compared annual rates of diarrhea-related healthcare events during prevaccine years 2005 and 2006 with postvaccine years 2008 and 2009 to examine the national burden of healthcare utilization for all-cause diarrhea.
RESULTS: Among sentinel surveillance hospitals, rotavirus hospitalization rates among children < 5 years of age declined by 81% (95% confidence interval [CI]: 78%-84%) in 2008 when 2-dose rotavirus vaccine coverage was 50% among infants < 1 year; the decline was 69% (95% CI: 65%-73%) in 2009 when 2-dose vaccine coverage was 61% among infants < 1 year, compared with 2006. The greatest declines were observed in children ≤ 1 year of age, although sizeable reductions were also observed among children ≥ 2 years in 2008. National diarrhea-related healthcare visits during rotavirus season decreased by 48% (95% CI: 47%-48%) in 2008 and by 35% (95% CI: 34%-35%) in 2009 compared with the mean rate from the 2005 and 2006 rotavirus seasons.
CONCLUSIONS: Rotavirus vaccination had a substantial public health impact on rotavirus disease and overall diarrhea events in El Salvador. Important age-related changes in diarrheal incidence emphasize the need for ongoing rotavirus surveillance after vaccine introduction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21048524     DOI: 10.1097/INF.0b013e3181fefa05

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  38 in total

Review 1.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

Review 2.  New insights into rotavirus vaccines.

Authors:  Chiara Mameli; Valentina Fabiano; Gian Vincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

Review 3.  Overcoming perceptions of financial barriers to rotavirus vaccine introduction in Asia.

Authors:  E Anthony S Nelson; Ciro A de Quadros; Mathuram Santosham; Umesh D Parashar; Duncan Steele
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

4.  Impact of Rotavirus Vaccination on Hospitalizations and Deaths From Childhood Gastroenteritis in Botswana.

Authors:  Leslie A Enane; Paul A Gastañaduy; David M Goldfarb; Jeffrey M Pernica; Margaret Mokomane; Banno Moorad; Lingani Masole; Jacqueline E Tate; Umesh D Parashar; Andrew P Steenhoff
Journal:  Clin Infect Dis       Date:  2016-05-01       Impact factor: 9.079

Review 5.  Rotavirus vaccines: current status and future considerations.

Authors:  Catherine Yen; Jacqueline E Tate; Terri B Hyde; Margaret M Cortese; Benjamin A Lopman; Baoming Jiang; Roger I Glass; Umesh D Parashar
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

6.  Investigation of a regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human rotavirus vaccine, Rotarix: approach and outcome.

Authors:  Gary Dubin; Jean-François Toussaint; Jean-Pol Cassart; Barbara Howe; Donna Boyce; Leonard Friedland; Remon Abu-Elyazeed; Sylviane Poncelet; Htay Htay Han; Serge Debrus
Journal:  Hum Vaccin Immunother       Date:  2013-08-28       Impact factor: 3.452

7.  Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine.

Authors:  Daniel Cowley; Karen Boniface; Nada Bogdanovic-Sakran; Carl D Kirkwood; Julie E Bines
Journal:  Hum Vaccin Immunother       Date:  2017-05-08       Impact factor: 3.452

Review 8.  Rotavirus vaccines: update on global impact and future priorities.

Authors:  Catherine Yen; Jacqueline E Tate; Manish M Patel; Margaret M Cortese; Benjamin Lopman; Jessica Fleming; Kristen Lewis; Baoming Jiang; Jon Gentsch; Duncan Steele; Umesh D Parashar
Journal:  Hum Vaccin       Date:  2011-12-01

9.  Rotavirus Infection and Disease in a Multisite Birth Cohort: Results From the MAL-ED Study.

Authors:  Venkata Raghava Mohan; Ramanujam Karthikeyan; Sudhir Babji; Monica McGrath; Sanjaya Shrestha; Jasmin Shrestha; Estomih Mdumah; Caroline Amour; Amidou Samie; Emanuel Nyathi; Rashidul Haque; Shahida Qureshi; Pablo Peñataro Yori; Aldo A M Lima; Ladaporn Bodhidatta; Erling Svensen; Pascal Bessong; Tahmeed Ahmed; Jessica C Seidman; Anita K M Zaidi; Margaret N Kosek; Richard L Guerrant; Jean Gratz; James A Platts-Mills; Dennis R Lang; Michael Gottlieb; Eric R Houpt; Gagandeep Kang
Journal:  J Infect Dis       Date:  2017-08-01       Impact factor: 5.226

10.  Does a monovalent inactivated human rotavirus vaccine induce heterotypic immunity? Evidence from animal studies.

Authors:  Baoming Jiang; Yuhuan Wang; Roger I Glass
Journal:  Hum Vaccin Immunother       Date:  2013-06-06       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.